Title: Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates
VOLUME: 11 ISSUE: 11
Author(s):Gustav Boije af Gennas, Virpi Talman, Jari Yli-Kauhaluoma, Raimo K Tuominen and Elina Ekokoski
Affiliation:Division of Pharmacology and Toxicology, Faculty of Pharmacy, P.O.Box 56 (Viikinkaari 5 E), FI-00014 University of Helsinki, Finland.
Keywords:Protein kinase C, C1 domain, drug discovery, cancer, Alzheimer's disease, bryostatins, ingenol-3-angelate, DAGlactones, signal transduction of G-protein, PKC, drug development pipeline, C1 domain-binding compounds
Abstract: The second messenger diacylglycerol (DAG) plays a central role in the signal transduction of G-protein coupled receptors and receptor tyrosine kinases by binding to C1 domain of effector proteins. C1 domain was first identified in protein kinase C (PKC) which comprises a family of ten isoforms that play roles in diverse cellular processes such as proliferation, apoptosis and differentiation. Aberrant signaling through PKC isoforms and other C1 domain-containing proteins has been implicated in several pathological disorders. Drug discovery concerning C1 domains has exploited both natural products and rationally designed compounds. Currently, molecules from several classes of C1 domain-binding compounds are in clinical trials; however, still more have the potential to enter the drug development pipeline. This review gives a summary of the recent developments in C1 domain-binding compounds.
